Infusion of iodine-based contrast agents into poly(p-dioxanone) as a radiopaque resorbable IVC filter
- 305 Downloads
To determine the feasibility of infusing resorbable inferior vena cava (IVC) filter with iodine-based contrast agents to produce a radiopaque, computed tomography (CT)-visible IVC filter. Infused poly(p-dioxanone) (PPDO) was obtained by incubating PPDO in different concentrations of 4-iodobenzoyl chloride (IBC) and 2,3,5-triiodobenzoic acid (TIBA). Characterizations of infused and nascent PPDO were done using elemental analysis, micro-CT, tensile strength analysis, scanning electron microscopy, and differential scanning calorimetry. Elemental analysis showed percentage loading of 1.07 ± 0.08 for IBC and 0.73 ± 0.01 for TIBA. The iodine loading remained the same within 2 weeks for TIBA but decreased to about 80 % with IBC when subjected to physiological conditions. Micro-CT images showed increased attenuation of the infused PPDO compared with the nascent PPDO. The Hounsfield unit values for infused and nascent sutures were 110 ± 40 and 153 ± 53 for PPDO infused with 2 mg/mL IBC and TIBA, respectively, but only 11.35 ± 2 for nascent PPDO. In contrast the HU for bone was 116 ± 37. Tensile strength analysis showed maximum loads of 1.01 ± 0.43 kg and 10.02 ± 0.54 kg for IBC and TIBA, respectively, and 10.10 ± 0.64 kg for nascent PPDO. Scanning electron microscopy showed that the morphology of the PPDO surface did not change after coating and preliminary cytotoxicity assay showed no killing effect on Hela cells. PPDO infused with a contrast agent is significantly more radiopaque than nascent PPDO on micro-CT imaging. This radiopacity could allow the position and integrity of infused resorbable IVC filter to be monitored while it is in place, thus increasing its safety and efficacy as a medical device.
KeywordsInferior Vena Cava Hounsfield Unit Triclosan TIBA Inferior Vena Cava Filter
We thank Sarah Bronson and Dawn Chalaire for editing the manuscript. This work was supported in part by the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center, the John S. Dunn Foundation, and The University of Texas MD Anderson Cancer Center’s Cancer Center Support Grant CA016672 from the National Institutes of Health for the small-animal imaging and veterinary pathology core facilities. We would like to thank Kiersten Maldonado, Charles Kingsley, Jorge de la Cerda, and Keith Michel for providing assistance in micro-CT imaging.
- 3.Society of Interventional Radiology. IVC filters: Society of Interventional Radiology leads in patient care, safety, research. 2011. http://www.sirweb.org/news/newsPDF/Release_JVIR_IVCF_Nov11_final.pdf. Accessed 30 Apr 2014.
- 7.Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, Cipolle M, Comerota AJ, Millward SF, Rogers FB, Sacks D, Venbrux AC. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006;17:449–59.CrossRefGoogle Scholar
- 8.Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, McNally M, Jacoby RC, Link D, Janczyk RJ, Ivascu FA, McCann M, Obeid F, Hoff WS, McQuay N, Tieu BH, Schreiber MA, Nirula R, Brasel K, Dunn JA, Gambrell D, Huckfeldt R, Harper J, Schaffer KB, Tominaga GT, Vinces FY, Sperling D, Hoyt D, Coimbra R, Rosengart MR, Forsythe R, Cothren C, Moore EE, Haut ER, Hayanga AJ, Hird L, White C, Grossman J, Nagy K, Livaudais W, Wood R, Zengerink I, Kortbeek JB. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma. 2007;62:17–25.CrossRefGoogle Scholar
- 11.U.S. Food and Drug Administration. Removing retrievable inferior vena cava filters: FDA safety communication. May 6, 2014. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm. Accessed 30 July 2014.